Komori
Revision to earnings forecast4547KISSEI PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding Revisions to Earnings Forecasts

The consolidated earnings forecast for the six months ended September 2026 was revised, with upward revisions to revenue, operating income and ordinary income. However, interim net income attributable to owners of the parent was revised downward because an extraordinary loss related to Tabuneos assets is expected.

Worth reading
64In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
-2300
¥ million
Wording
Avoiding a definitive answer
How definitive the wording is.

Revised forecast

Fiscal year ending March 2027 · Second quarter (cumulative)Previous forecast published 31 July 2026
Net Sales44,800→45,500million
+1.6%
Operating profit500→1,600million
+220.0%
Ordinary income1,700→2,900million
+70.6%
Profit attributable to owners of the parent7,400→5,100million
-31.1%
Net income per share176.92→122.19yen and sen
-30.9%

The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.

Reason for the revision

Revenue, operating income and ordinary income were revised upward due to growth in イセルティ, ベオーバ and コルスバ, an increase in co-promotion fees, stronger-than-expected performance in the information services business, and greater efficiency in selling, general and administrative expenses. Interim net income was revised downward because an extraordinary loss on related assets will be recognised in connection with administrative procedures, including the cancellation of Tabuneos' marketing authorisation.

Details and amount of extraordinary loss

Extraordinary loss on assets related to Tabuneos, including inventories and long-term prepaid expenses. Amount: Not disclosed.

Previous-period resultsRevenue: ¥45,831 million; operating loss: ¥6,837 million; ordinary loss: ¥5,622 million; interim net income attributable to owners of the parent: ¥7,784 million; interim net income per share: ¥186.81 (second quarter of the fiscal year ending March 2026)
Consolidated / non-consolidatedConsolidated
Revised forecast
ItemDetails
Net Sales¥44,800 million → ¥45,500 million(+1.6%)
Operating profit¥500 million → ¥1,600 million(+220.0%)
Ordinary income¥1,700 million → ¥2,900 million(+70.6%)
Profit attributable to owners of the parent¥7,400 million → ¥5,100 million(-31.1%)
Net income per share176.92 yen and sen → 122.19 yen and sen
Fiscal Period CoveredFiscal year ending March 2027
Period CoveredSecond quarter (cumulative)
Publication date of previous forecast31 July 2026
Previous-period resultsRevenue: ¥45,831 million; operating loss: ¥6,837 million; ordinary loss: ¥5,622 million; interim net income attributable to owners of the parent: ¥7,784 million; interim net income per share: ¥186.81 (second quarter of the fiscal year ending March 2026)
Reason for the revisionRevenue, operating income and ordinary income were revised upward due to growth in イセルティ, ベオーバ and コルスバ, an increase in co-promotion fees, stronger-than-expected performance in the information services business, and greater efficiency in selling, general and administrative expenses. Interim net income was revised downward because an extraordinary loss on related assets will be recognised in connection with administrative procedures, including the cancellation of Tabuneos' marketing authorisation.
Details and amount of extraordinary lossExtraordinary loss on assets related to Tabuneos, including inventories and long-term prepaid expenses. Amount: Not disclosed.
Consolidated / non-consolidatedConsolidated
Items this document does not state (1)
Dividend forecast revision

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Revenue, operating income and ordinary income were revised upward due to growth in イセルティ, ベオーバ and コルスバ, an increase in co-promotion fees, stronger-than-expected performance in the information services business, and greater efficiency in selling, general and administrative expenses. Meanwhile, interim net income was revised downward because an extraordinary loss on Tabuneos-related assets will be recognised in connection with administrative procedures, including the cancellation of Tabuneos' marketing authorisation.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Revisions to Earnings Forecasts | KISSEI PHARMACEUTICAL CO.,LTD. (4547) timely disclosure | Komori